Biotech Startups

AndzonBio2 develops neuroinflammation therapies targeting STING and lipid peroxidation pathways, aiming to intervene in central nervous system diseases through translational research and drug development.

1 investor

Anebulo Pharmaceuticals is developing selonabant, a drug candidate intended to reverse cannabis-induced toxicities, including acute CNS depression in children and acute cannabinoid intoxication in adults. The company is a clinical-stage pharmaceutical developer targeting conditions for which there are no approved treatments.

1 investor

Anesiva is a biopharmaceutical company developing Nexletol for diet management.

1 investor

Angel City Bio is a physician-scientist founded pharmaceutical company developing bile-acid-based treatments for gastrointestinal diseases, with programs targeting indications such as GLP-1-associated gallbladder disease and Crohn's disease. Its approach uses enterohepatic recirculation biology and 505(b)(2) regulatory pathways to pursue multiple drug targets.

1 investor

AngenMed develops neoantigen-targeting cell-based cancer immunotherapies, including dendritic cell vaccines and neoantigen-specific T cell products personalized to each patient's tumor mutations. The company operates in the biotech and cancer therapeutics space, using tumor sequencing to identify neoantigens and manufacture DC and T-cell products.

1 investor

Angiocrine Bioscience is a biotechnology company focused on developing therapies, presenting its work under a science-driven mission to cure disease.

1 investor

Anju Software provides data management and integration solutions for pharmaceutical companies, clinical research organizations, and medical device companies. The company specializes in life science information management systems that enable data flow and third-party system connectivity.

1 investor

Ankyra Therapeutics is a biopharmaceutical company developing drugs, with a team that has collectively contributed to bringing seven drugs to global market approval.

1 investor

Anocis is a pharmaceutical drug discovery company focused on early-stage development in neuroscience, particularly ion channel research. The company serves pharmaceutical and biotech clients seeking collaborative drug discovery services and technologies.

1 investor

Anodyne Chemistries produces formic acid, formaldehyde, and methanol through enzymatic conversion of CO2, offering multiple purity grades for industrial purchase.

1 investor

Anomaly develops functional ingredients through advanced fermentation, engineering microbes to convert simple sugars into ingredients for nutrition, crop protection, and personal care. It aims to replace extraction-based ingredient supply chains with on-demand biomanufacturing.

1 investor

Another Food develops cell-cultured coffee, producing coffee from cultivated coffee plant cells in a lab rather than growing beans on farms. It positions its technology as using less water, fewer greenhouse gas emissions and no land to create a nature-identical coffee product.

1 investor

ANRis develops nucleic acid therapeutics using proprietary SNPD-siRNA technology for drug discovery and treatment delivery in medical and pharmaceutical applications.

1 investor

Ansella Therapeutics develops novel vaginal formulations for women's health conditions using biomimetic materials science and biomedical engineering, focused on treating menopause, vaginal dryness, dyspareunia, vaginal mucositis, endometriosis, uterine fibroids, and vaginal infections.

1 investor

AnserBio develops an oncology biotherapy that restores functional p53 tumor suppressor protein by delivering it through proprietary cell-derived nanovesicles (exosomes). It targets p53-mutant cancers with high unmet need, including colon, bladder, ovarian cancer, and glioblastoma.

1 investor

Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments for drug-resistant, Gram-negative bacterial infections identified as critical priorities by the WHO and CDC, with a focus on life-threatening hospital-acquired infections. Its lead program, Meropenem-Pilabactam, is a β-lactam/β-lactamase inhibitor combination for treating multidrug-resistant infections in hospital wards and ICUs.

1 investor

Antalgenics develops drugs and neurocosmetical products targeting dermatological and inflammatory conditions such as psoriatic pruritus, arthritic pain, and sensitive skin. The company focuses on pharmaceutical and cosmetic ingredient innovation for healthcare and personal care markets.

1 investor

Antaros Medical is a development partner to the pharmaceutical industry that uses medical imaging to provide evidence-based decision support during clinical drug development. It combines imaging technology with expertise in drug development and disease mechanisms.

1 investor

Antelope Surgical Solutions develops multimodal small-molecule radioligand agents that bind to cancer cells for diagnostic, radiotherapeutic, and fluorescence-guided surgical use, making tumor margins visible to surgeons during operations. The company operates a GMP manufacturing facility with robotic high-throughput synthesis and has received its first FDA IND clearance for its lead agent.

1 investor

Anthriq develops the Human Body API, a hardware and software platform that reads and writes human biosignals and psychophysiological data to enable developers to build brain-computer interface and human-computer interaction products. The company provides a full-stack foundation for innovators working on neurotech and biotech applications.

1 investor

1 investor

Anumana is an AI-driven health technology company developing software-as-a-medical-device (SaMD) solutions that apply AI to standard 12-lead ECG data to detect early signs of cardiovascular disease and support clinical decision-making. Its portfolio includes FDA-cleared ECG-AI algorithms, generative imaging applications, and real-time procedural support tools for use across diagnostic and intraprocedural cardiac care.

1 investor

Anuncia Medical develops medical technology focused on cerebrospinal fluid (CSF) science and clinical strategy to advance hydrocephalus treatment. The company combines decades of medtech expertise to serve the hydrocephalus care market.

1 investor

Anvil Diagnostics develops molecular diagnostic tests for invasive infections using proprietary SKIP-Seq technology that combines PCR speed with sequencing breadth. The company serves clinical laboratories and healthcare providers seeking rapid, direct-from-blood pathogen identification and antimicrobial guidance.

1 investor